Here's Why Oscar Health, Inc. (OSCR) Fell More Than Broader Market
In the latest trading session, Oscar HealthOSCR--, Inc. (OSCR) closed at $13.30, marking a -1.92% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.28%.
Prior to today's trading, shares of the company had lost 1.02% was narrower than the Finance sector's loss of 6.73% and the S&P 500's loss of 3.59%.
Analysts and investors alike will be keeping a close eye on the performance of Oscar Health, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.21, signifying a 31.52% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $4.89 billion, showing a 60.62% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.2 per share and a revenue of $18.91 billion, representing changes of +111.83% and +61.62%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Oscar Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Oscar Health, Inc. is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, Oscar Health, Inc. is holding a Forward P/E ratio of 66.69. For comparison, its industry has an average Forward P/E of 9.17, which means Oscar Health, Inc. is trading at a premium to the group.
The Insurance - Multi line industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oscar Health, Inc. (OSCR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet